Newsroom | Galderma US

Cetaphil® Launches Innovative Digital Campaign to Connect with Millions of Consumers Experiencing Skin Sensitivity

Differin® Celebrates Fourth Annual Retinoid Education Week by Offering People with Acne the Chance to “Get Clear” Through Large-Scale Product Giveaway

Galderma Receives FDA Approval for Restylane® Defyne for Chin Augmentation

Galderma Announces Launch of Face for Change Program

Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)

Cetaphil Taps Rachel Brosnahan as Creative Consultant for New “Up Close and Sensitive” Digital Campaign

Galderma To Present Five Abstracts in Support of Novel Aesthetics Solutions and Pipeline at ASDS 2020 Annual Meeting

Cetaphil® Unveils Premium Product Line with New HydroSensitiv™ Complex That Delivers 48-Hour Hydration

On International Kissing Day, Galderma Shares First-of-its-Kind Phase IV Kissability Study Results Showing Both Subject and Partner Satisfaction with Restylane® Kysse

Galderma receives FDA approval for Restylane® Kysse, a new hyaluronic acid (HA) Filler specifically designed and indicated to add fullness to the lips and help smooth the wrinkles above the mouth

Galderma Announces an Acceleration of its Growth and Expansion Plans to Support Aesthetic Providers

Differin® Launches Clear90™ App, to Support People with Acne on Their Clear Skin Journey as Part of Third-Annual Retinoid Education Week

Fort Worth’s Galderma, Maker of Cetaphil, Presents the 5th Annual Wonder Run 5K and Kids 1K to Benefit Children’s Skin Disease Foundation